Royalty Records. Commencing as of the date of First Commercial Sale of the first Licensed Product hereunder, Licensee and its Affiliates and Sublicensees shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate records of sales by Licensee or its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in sufficient detail to allow the accuracy of the payments hereunder to be confirmed.
Royalty Records. Licensee shall keep true books of account containing an accurate record of all data necessary for the determination of the amounts payable to or on behalf of Licensor under this Agreement, and maintain the same throughout the Term and for two (2) years thereafter. Licensor may from time to time, during regular business hours and upon reasonable advance notice, examine the applicable records of Licensee in order to verify payments, record keeping requirements and compliance by Licensee with its obligations hereunder. Such examinations shall be conducted during regular business hours at the Licensee’s offices by a certified public accountant selected by Licensor. All costs and fees relating to each such examination shall be borne by Licensor, provided, however, that if any such examination discloses an underpayment or underexpenditure by Licensee exceeding * percent (*%) or USD$*, Licensee shall pay the costs and fees thereof. Licensor shall conduct no more than one (1) such examination during a twelve (12)-month period.
Royalty Records. With respect to payments to be made under Sections 5.1 through 5.4, inclusive, Celgene agrees to keep, and to require its Affiliates and Sublicensees to keep, for at least [***] from the end of the Calendar Year to which they pertain, complete and accurate records of transfer and sales by Celgene or its Affiliates or Sublicensees, as the case may be, of each Co-Co Product, in sufficient detail to allow the accuracy of the payments made thereunder to be confirmed
Royalty Records. Kyowa Kirin will keep and maintain, and shall cause its Permitted Sublicensees to maintain, complete and accurate books and records necessary to permit calculation and verification of Sales Royalties due under Section 7.3. Kyowa Kirin will maintain such books and records for [***] years after the applicable book or record was created, or such longer period as may be required by Applicable Law.
Royalty Records. Licensee and its Affiliates and Sublicensees shall keep, for at least three (3) years from the end of the calendar year to which they pertain, complete and accurate records of transfer and sales by Licensee or its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in sufficient detail to allow the accuracy of the payments hereunder to be confirmed.
Royalty Records. PSW shall keep or cause to be kept full and accurate accounts and records of all transactions made by it and by its Resellers under this Agreement in form such that all amounts owing hereunder to CCSI may be readily and accurately determined. PSW shall use commercially reasonable efforts to assure that its Resellers are (a) accurately reporting to PSW all transactions with Customers and (b) otherwise complying with this Agreement. All books of account and records kept under this Section 5 shall be retained by PSW for at least two (2) years after the termination of this Agreement.
Royalty Records. With respect to payments to be made under Sections 5.1 through 5.4, inclusive, Celgene agrees to keep, and to require its Affiliates and Sublicensees to keep, for at least [***] from the end of [***], complete and accurate records of transfer and sales by Celgene or its Affiliates or Sublicensees, as the case may be, of each Licensed Product and related Licensed Diagnostic Product, in sufficient detail to allow the accuracy of the payments made thereunder to be confirmed. Notwithstanding the foregoing, if a Juno Upstream Agreement requires such records to be maintained for longer time periods or imposes additional requirements on licensees or sublicensees with respect to the relevant License Net Sales, Juno will disclose to Celgene in advance of the first License Net Sales the applicable requirements, and the Parties will cooperate in good faith to agree upon a manner for complying with such Juno Upstream Agreement.
Royalty Records. Schering will maintain complete and accurate records which are relevant to the calculation of Net Sales and royalties on a country-by- country basis and Annual Worldwide Net Sales under this Agreement and such records shall be open during reasonable business hours for a period of three (3) years from creation of individual records for examination at 3DP's expense and not more often than once each year by a firm of certified public accountants selected by 3DP and reasonably acceptable to Schering, for the sole purpose of verifying for 3DP the correctness of calculations and classifications of such Net Sales or royalty calculations or Annual Worldwide Net Sales made under this Agreement. 3DP shall bear its own costs related to such audit; provided that, for any underpayments greater than five (5) percent by Schering, Schering shall pay 3DP the amount of underpayment, interest as provided for in Section 5.4 from the time the amount was due and 3DP's out-of-pocket expenses. For any underpayments less than five (5) percent by Schering found under this Section, Schering shall pay 3DP the amount of underpayment. Any overpayments by Schering will be credited to future royalties. Any records or accounting information received from the Schering shall be Confidential Information for purposes of Article 6. Results of any such audit shall be provided to both Parties, subject to Article 6.
Royalty Records. Each Payer must keep, or cause to be kept, true and accurate Royalty Records in accordance with the Accounting Standards and generally accepted Australian mining industry practice.
Royalty Records. CRISPR and its Affiliates and Sublicensees shall keep, for at least [*****] years from the end of the Calendar Year to which they pertain, complete and accurate records of sales by CRISPR, its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in sufficient detail to allow the accuracy of the payments hereunder to be confirmed.
